Download
00270_2024_Article_3717.pdf 955,36KB
WeightNameValue
1000 Titel
  • Intravenous Opioid Medication with Piritramide Reduces the Risk of Pneumothorax During CT-Guided Percutaneous Core Biopsy of the Lung
1000 Autor/in
  1. Goetz, Andrea |
  2. Poschenrieder, Florian |
  3. Steer, Frederike Georgine |
  4. Zeman, Florian |
  5. Lange, Tobias J. |
  6. Thurn, Sylvia |
  7. Greiner, Barbara |
  8. Stroszczynski, Christian |
  9. Uller, Wibke |
  10. Hamer, Okka |
  11. Hammer, Simone |
1000 Verlag Springer US
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-19
1000 Erschienen in
1000 Quellenangabe
  • 47(5):621-631
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00270-024-03717-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11074218/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>CT-guided percutaneous core biopsy of the lung is usually performed under local anesthesia, but can also be conducted under additional systemic opioid medication. The purpose of this retrospective study was to assess the effect of intravenous piritramide application on the pneumothorax rate and to identify risk factors for post-biopsy pneumothorax.</jats:p> </jats:sec><jats:sec> <jats:title>Materials and Methods</jats:title> <jats:p>One hundred and seventy-one core biopsies of the lung were included in this retrospective single center study. The incidence of pneumothorax and chest tube placement was evaluated. Patient-, procedure- and target-related variables were analyzed by univariate and multivariable logistic regression analysis.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The overall incidence of pneumothorax was 39.2% (67/171). The pneumothorax rate was 31.5% (29/92) in patients who received intravenous piritramide and 48.1% (38/79) in patients who did not receive piritramide. In multivariable logistic regression analysis periinterventional piritramide application proved to be the only independent factor to reduce the risk of pneumothorax (odds ratio 0.46, 95%-confidence interval 0.24, 0.88; <jats:italic>p</jats:italic> = 0.018). Two or more pleura passages (odds ratio 3.38, 95%-confidence interval: 1.15, 9.87; <jats:italic>p</jats:italic> = 0.026) and prone position of the patient (odds ratio 2.27, 95%-confidence interval: 1.04, 4.94; <jats:italic>p</jats:italic> = 0.039) were independent risk factors for a higher pneumothorax rate.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Procedural opioid medication with piritramide proved to be a previously undisclosed factor decreasing the risk of pneumothorax associated with CT-guided percutaneous core biopsy of the lung.</jats:p> </jats:sec><jats:sec> <jats:title>Level of Evidence 4</jats:title> <jats:p>small study cohort.</jats:p> </jats:sec><jats:sec> <jats:title>Graphic Abstract</jats:title> </jats:sec>
1000 Sacherschließung
lokal Lung/pathology [MeSH]
lokal Clinical Investigation
lokal Image-Guided Biopsy/methods [MeSH]
lokal Aged [MeSH]
lokal Risk Factors [MeSH]
lokal Tomography, X-Ray Computed/methods [MeSH]
lokal Analgesics
lokal Risk factors
lokal Pneumothorax/prevention
lokal Opioid
lokal Male [MeSH]
lokal Image-Guided Biopsy/adverse effects [MeSH]
lokal Pirinitramide/administration
lokal Biopsy
lokal Non-Vascular Interventions
lokal Piritramide
lokal Female [MeSH]
lokal Computed tomography
lokal Analgesics, Opioid/administration
lokal Pneumothorax
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Incidence [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Lung/diagnostic imaging [MeSH]
lokal Pneumothorax/etiology [MeSH]
lokal Radiography, Interventional/methods [MeSH]
lokal Pirinitramide/therapeutic use [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0009-0009-0588-1963|https://frl.publisso.de/adhoc/uri/UG9zY2hlbnJpZWRlciwgRmxvcmlhbg==|https://frl.publisso.de/adhoc/uri/U3RlZXIsIEZyZWRlcmlrZSBHZW9yZ2luZQ==|https://frl.publisso.de/adhoc/uri/WmVtYW4sIEZsb3JpYW4=|https://frl.publisso.de/adhoc/uri/TGFuZ2UsIFRvYmlhcyBKLg==|https://frl.publisso.de/adhoc/uri/VGh1cm4sIFN5bHZpYQ==|https://frl.publisso.de/adhoc/uri/R3JlaW5lciwgQmFyYmFyYQ==|https://frl.publisso.de/adhoc/uri/U3Ryb3N6Y3p5bnNraSwgQ2hyaXN0aWFu|https://frl.publisso.de/adhoc/uri/VWxsZXIsIFdpYmtl|https://frl.publisso.de/adhoc/uri/SGFtZXIsIE9ra2E=|https://frl.publisso.de/adhoc/uri/SGFtbWVyLCBTaW1vbmU=
1000 Hinweis
  • DeepGreen-ID: 8f7fb2944525488b9f66b2d0b53f68bc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Regensburg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Regensburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6509397.rdf
1000 Erstellt am 2025-02-06T20:13:36.591+0100
1000 Erstellt von 322
1000 beschreibt frl:6509397
1000 Zuletzt bearbeitet 2025-09-12T13:29:19.956+0200
1000 Objekt bearb. Fri Sep 12 13:29:19 CEST 2025
1000 Vgl. frl:6509397
1000 Oai Id
  1. oai:frl.publisso.de:frl:6509397 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source